MedTrace Logo

The Effects of Anesthetic Techniques and Palonosetron Administration on the Incidence of PONV

NCT02809378 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2017-07-21

No results posted yet for this study

Summary

The incidence of postoperative nausea and vomiting (PONV) after thyroidectomy have been shown to be relatively high compared other surgeries, with a reported incidence 65-75 %. PONV may increase patient discomfort, delay patient discharge, and increase the cost of patient care, the risk of postoperative bleeding which may potentially cause airway obstruction.

It is reported that the maintenance of anesthesia with propofol-remifentanil or sevoflurane-propofol-remifentanil decreased the incidence of PONV compared sevoflurane alone, but failed to demonstrate the decreased incidence of PONV in 6-24 hr postoperative period in patients undergoing thyroidectomy. Administration of Palonosetron, newly developed 5-HT3 antagonists with long half life (48 hrs) may decrease the incidence of PONV particularly during this period.

The purpose of this study was to evaluate and compare the incidence of PONV after thyroidectomy with three different anesthetic methods, sevoflurane or sevoflurane-propofol-remifentanil or sevoflurane-propofol-remifentanil-palonosetron in woman patients.

Conditions

  • PONV
  • Palonosetron
  • Anesthesia

Interventions

DRUG

Palonosetron

newly developed 5-HT3 antagonists with long half life (48 hrs) intravenous administration prior to anesthesia induction

DRUG

sevoflurane

Inhalational anesthetics Halogenated.

DRUG

remifentanil

ultra-short acting opioid anesthetics

DRUG

pentothal sodium

intra-venous anesthetics for anesthesia induction

DRUG

propofol

intra-venous anesthetics for anesthesia induction and maintenance

Sponsors & Collaborators

  • HK inno.N Corporation

    collaborator INDUSTRY

  • Ajou University School of Medicine

    lead OTHER

Principal Investigators

  • Dae Hee Kim, MD · Ajou University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2017-04-20
Completion
2017-04-20

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02809378 on ClinicalTrials.gov